Why belly fat is more dangerous than fat on your hips

The science, in full

Body fat is not one tissue but several, and location changes its behaviour. Subcutaneous fat lies just under the skin and drains into the general circulation. Visceral adipose tissue sits inside the abdominal cavity around the intestines and liver, and much of its venous blood drains through the portal vein directly into the liver before reaching the rest of the body. This anatomy, combined with the fact that visceral fat cells are more metabolically restless than subcutaneous ones, is the starting point for why the two depots carry such different risks.

The oldest mechanistic idea is the portal theory. Visceral adipocytes are relatively insensitive to the fat-storing signal of insulin and readily break down their stored fat, releasing free fatty acids. Because these cells drain into the portal vein, the liver is exposed to a comparatively high tide of fatty acids and inflammatory molecules. This can push the liver toward overproducing glucose and VLDL particles and toward hepatic insulin resistance. The portal theory is biologically attractive but remains debated, since visceral fat is only one of several sources of fatty acids reaching the liver, and its exact quantitative contribution is still uncertain.

Inflammation is the second major thread. As visceral fat expands, its cells outgrow their blood supply, some become stressed, and immune cells, particularly macrophages, move in. This tissue then secretes pro-inflammatory signals such as interleukin-6 and tumour necrosis factor alpha, while producing less adiponectin, an adipokine that normally improves insulin sensitivity and calms inflammation. The result is a chronic, low-grade inflammatory state sometimes called metaflammation, which interferes with insulin signalling in muscle and liver and links obesity to metabolic disease.

A third mechanism is ectopic fat. Each person appears to have a personal limit for how much fat their subcutaneous depots can safely store. Once that capacity is exceeded, fat spills over into places it does not belong: the liver, skeletal muscle, the pancreas and around the heart. Fat in the liver drives non-alcoholic fatty liver disease and worsens whole-body insulin resistance, and ectopic fat generally tracks with visceral fat. In this view, visceral fat is partly a visible marker that the safe storage system is overwhelmed.

The epidemiology supports the idea that where fat sits matters, not just how much there is. In the INTERHEART case-control study of about 27,000 people across 52 countries, waist-to-hip ratio showed a graded relationship with first heart attack, and it remained a strong predictor after adjustment while the association with body mass index was substantially weakened. The EPIC study of more than 350,000 Europeans found that waist circumference and waist-to-hip ratio were associated with higher mortality even among people whose BMI was in the normal range, underlining that central fat carries risk that overall weight can miss.

This is why waist measures often outperform BMI for risk. A pooled analysis of about 650,000 adults reported that larger waist circumference was associated with higher mortality within every BMI category. Meta-analyses of waist-to-height ratio suggest it screens for cardiometabolic risk factors at least as well as, and often better than, waist circumference or BMI, and that a simple boundary of 0.5, meaning your waist should be less than half your height, works reasonably across populations. A recent meta-analysis found that higher waist-to-height ratio was associated with roughly 16 to 23 percent higher all-cause mortality and an even larger increase in cardiovascular mortality.

Clinical guidance has moved in this direction. Traditional waist thresholds of 102 cm in men and 88 cm in women flag substantially increased risk, though lower cut-offs (around 94 cm and 80 cm) mark the point where risk begins to rise, and appropriate values differ by ancestry, with lower thresholds for South Asian and East Asian populations. An international consensus statement has argued that waist circumference should be measured routinely as a vital sign alongside BMI, precisely because it captures the abdominal fat that BMI alone overlooks.

Several caveats keep this honest. Most of the human evidence is observational, so it establishes strong and consistent association rather than proving that visceral fat itself causes each outcome; shared drivers such as diet, physical inactivity, genetics and sleep contribute too. A tape measure is only a proxy: imaging with CT or MRI is the gold standard for actually quantifying visceral fat, and two people with the same waist can have different amounts of it. Subcutaneous fat is not entirely inert either, and lower-body fat may be relatively protective, so the picture is one of a spectrum rather than good fat versus bad fat.

The practical takeaway is measured. Visceral fat is metabolically active tissue that plausibly drives insulin resistance, inflammation and ectopic fat deposition, and central adiposity is one of the more useful, low-cost signals of cardiometabolic risk we have. Encouragingly, it is also responsive: it tends to fall early with increased activity, better diet quality, reduced alcohol and modest weight loss. A rising waist, or one already past these thresholds, is a reason to review the whole cardiometabolic picture with your own doctor rather than a verdict in itself.

Putting this into practice. Belly fat responds faster than almost any other fat, so start where it counts. Take a tape measure around your navel, relaxed and without pulling in, and note the number so you have an honest baseline to watch. Then go easier on the fast sugars and refined carbohydrates that feed this fat, and build in daily movement, a brisk walk after your biggest meal is a simple place to start. Keep sugary drinks and snacks out of the house rather than relying on willpower in the moment. You may not see much on the scales at first, but your waistline and your energy often notice before the numbers do.